Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01

BACKGROUND: Previous large trials of trastuzumab (TZM) demonstrated improved outcomes in patients with HER2-positive early breast cancer. However, its effectiveness and safety in Japanese patients is not yet clear. Recently, new anti-HER2 agents were developed to improve treatment outcomes, but the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Breast Cancer
Главные авторы: Yamashiro, Hiroyasu, Iwata, Hiroji, Masuda, Norikazu, Yamamoto, Naohito, Nishimura, Reiki, Ohtani, Shoichiro, Sato, Nobuaki, Takahashi, Masato, Kamio, Takako, Yamazaki, Kosuke, Saito, Tsuyoshi, Kato, Makoto, Lee, Tecchuu, Kuroi, Katsumasa, Takano, Toshimi, Yasuno, Shinji, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Japan 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7297820/
https://ncbi.nlm.nih.gov/pubmed/32060785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-020-01057-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы